Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 800 entries
Sorted by: Best Match Show Resources per page
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

World journal of virology

Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW.
PMID: 24175223
World J Virol. 2012 Dec 12;1(6):174-83. doi: 10.5501/wjv.v1.i6.174.

Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma (HCC) in patients chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). The approved medication for the treatment of chronic HBV...

Cite
Chen LP, Zhao J, Du Y, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012;1(6):174-83doi: 10.5501/wjv.v1.i6.174.
Chen, L. P., Zhao, J., Du, Y., Han, Y. F., Su, T., Zhang, H. W., & Cao, G. W. (2012). Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World journal of virology, 1(6), 174-83. https://doi.org/10.5501/wjv.v1.i6.174
Chen, Li-Ping, et al. "Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma." World journal of virology vol. 1,6 (2012): 174-83. doi: https://doi.org/10.5501/wjv.v1.i6.174
Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012 Dec 12;1(6):174-83. doi: 10.5501/wjv.v1.i6.174. PMID: 24175223; PMCID: PMC3782279.
Copy Download .nbib Format: NLM
Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Patassi A, Benaboud S, Landoh DE, Salou M, Dagnra AC, Saka B, Krivine A, Meritet JF, Pitché P, Salmon-Ceron D.
PMID: 27245734
S Afr Med J. 2016 May 10;106(6). doi: 10.7196/SAMJ.2016.v106i6.10312.

BACKGROUND: No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection.OBJECTIVE: To determine the prevalence of HBV and the risk of HBV drug resistance...

Cite
Patassi A, Benaboud S, Landoh DE, et al. Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences. S Afr Med J. 2016;106(6)doi: 10.7196/SAMJ.2016.v106i6.10312.
Patassi, A., Benaboud, S., Landoh, D. E., Salou, M., Dagnra, A. C., Saka, B., Krivine, A., Meritet, J. F., Pitché, P., & Salmon-Ceron, D. (2016). Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 106(6), . https://doi.org/10.7196/SAMJ.2016.v106i6.10312
Patassi, Akouda, et al. "Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences." South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde vol. 106,6 (2016). doi: https://doi.org/10.7196/SAMJ.2016.v106i6.10312
Patassi A, Benaboud S, Landoh DE, Salou M, Dagnra AC, Saka B, Krivine A, Meritet JF, Pitché P, Salmon-Ceron D. Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences. S Afr Med J. 2016 May 10;106(6). doi: 10.7196/SAMJ.2016.v106i6.10312. PMID: 27245734.
Copy Download .nbib Format: NLM
Current Options for the Therapy of Chronic Hepatitis B Infection.

Current infectious disease reports

Kioko Ono-Nita S, Kato N, Shiratori Y, Omata M.
PMID: 11286654
Curr Infect Dis Rep. 2001 Apr;3(2):137-142. doi: 10.1007/s11908-996-0036-2.

Until recently the only available treatment for chronic hepatitis B was interferon-alpha. Over the past few years a new class of antiviral has become available, the reverse transcriptase inhibitors. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor that was...

Cite
Kioko Ono-Nita S, Kato N, Shiratori Y, et al. Current Options for the Therapy of Chronic Hepatitis B Infection. Curr Infect Dis Rep. 2001;3(2):137-142doi: 10.1007/s11908-996-0036-2.
Kioko Ono-Nita, S., Kato, N., Shiratori, Y., & Omata, M. (2001). Current Options for the Therapy of Chronic Hepatitis B Infection. Current infectious disease reports, 3(2), 137-142. https://doi.org/10.1007/s11908-996-0036-2
Kioko Ono-Nita, Suzane, et al. "Current Options for the Therapy of Chronic Hepatitis B Infection." Current infectious disease reports vol. 3,2 (2001): 137-142. doi: https://doi.org/10.1007/s11908-996-0036-2
Kioko Ono-Nita S, Kato N, Shiratori Y, Omata M. Current Options for the Therapy of Chronic Hepatitis B Infection. Curr Infect Dis Rep. 2001 Apr;3(2):137-142. doi: 10.1007/s11908-996-0036-2. PMID: 11286654.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 11980386
Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses, which has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(1):37-55
Bayes, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(1), 37-55.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,1 (2002): 37-55.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55. PMID: 11980386.
Copy Download .nbib Format: NLM
Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine.

Hepatology research : the official journal of the Japan Society of Hepatology

Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M.
PMID: 11470630
Hepatol Res. 2001 Sep;21(1):76-84. doi: 10.1016/s1386-6346(01)00081-x.

Changes in the HBV DNA level during the treatment of patients with chronic hepatitis B with lamivudine were investigated by the transcription-mediated amplification (TMA) assay. Twenty-four patients treated with lamivudine (males:female= 20:4, age: 44.0+/-9.0 years, chronic hepatitis: 14, cirrhosis:...

Cite
Ide T, Kumashiro R, Hino T, et al. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res. 2001;21(1):76-84doi: 10.1016/s1386-6346(01)00081-x.
Ide, T., Kumashiro, R., Hino, T., Murashima, S., Ogata, K., Koga, Y., & Sata, M. (2001). Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatology research : the official journal of the Japan Society of Hepatology, 21(1), 76-84. https://doi.org/10.1016/s1386-6346(01)00081-x
Ide, T, et al. "Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine." Hepatology research : the official journal of the Japan Society of Hepatology vol. 21,1 (2001): 76-84. doi: https://doi.org/10.1016/s1386-6346(01)00081-x
Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res. 2001 Sep;21(1):76-84. doi: 10.1016/s1386-6346(01)00081-x. PMID: 11470630.
Copy Download .nbib Format: NLM
Proceedings of the international symposium on treatment of chronic hepatitis B infection with lamivudine, an oral antiviral drug.

Journal of medical virology

Maddrey W.
PMID: 10861646
J Med Virol. 2000 Jul;61(3):361. doi: 10.1002/1096-9071(200007)61:3<361::aid-jmv13>3.0.co;2-m.

No abstract available.

Cite
Maddrey W. Proceedings of the international symposium on treatment of chronic hepatitis B infection with lamivudine, an oral antiviral drug. J Med Virol. 2000;61(3):361doi: 10.1002/1096-9071(200007)61:3<361::aid-jmv13>3.0.co;2-m.
Maddrey, W. (2000). Proceedings of the international symposium on treatment of chronic hepatitis B infection with lamivudine, an oral antiviral drug. Journal of medical virology, 61(3), 361. https://doi.org/10.1002/1096-9071(200007)61:3<361::aid-jmv13>3.0.co;2-m
Maddrey. "Proceedings of the international symposium on treatment of chronic hepatitis B infection with lamivudine, an oral antiviral drug." Journal of medical virology vol. 61,3 (2000): 361. doi: https://doi.org/10.1002/1096-9071(200007)61:3<361::aid-jmv13>3.0.co;2-m
Maddrey W. Proceedings of the international symposium on treatment of chronic hepatitis B infection with lamivudine, an oral antiviral drug. J Med Virol. 2000 Jul;61(3):361. doi: 10.1002/1096-9071(200007)61:3<361::aid-jmv13>3.0.co;2-m. PMID: 10861646.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study.

International journal of immunopathology and pharmacology

Gianotti N, Setti M, Manconi PE, Leoncini F, Chiodo F, Minoli L, Moroni M, Angarano G, Mazzotta F, Carosi G, Antonelli G, Lazzarin A.
PMID: 12590875
Int J Immunopathol Pharmacol. 2002 May-Aug;15(2):129-139. doi: 10.1177/039463200201500208.

Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was studied in 527 HIV-1-infected patients, 342 responder and 185 non-responder to two NRTIs. Responders were followed for one year to assess the incidence of clinical failure. The prevalence of the 215Y/F...

Cite
Gianotti N, Setti M, Manconi PE, et al. Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. Int J Immunopathol Pharmacol. 2002;15(2):129-139doi: 10.1177/039463200201500208.
Gianotti, N., Setti, M., Manconi, P. E., Leoncini, F., Chiodo, F., Minoli, L., Moroni, M., Angarano, G., Mazzotta, F., Carosi, G., Antonelli, G., & Lazzarin, A. (2002). Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. International journal of immunopathology and pharmacology, 15(2), 129-139. https://doi.org/10.1177/039463200201500208
Gianotti, N., et al. "Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study." International journal of immunopathology and pharmacology vol. 15,2 (2002): 129-139. doi: https://doi.org/10.1177/039463200201500208
Gianotti N, Setti M, Manconi PE, Leoncini F, Chiodo F, Minoli L, Moroni M, Angarano G, Mazzotta F, Carosi G, Antonelli G, Lazzarin A. Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. Int J Immunopathol Pharmacol. 2002 May-Aug;15(2):129-139. doi: 10.1177/039463200201500208. PMID: 12590875.
Copy Download .nbib Format: NLM
[Preliminary observation on the efficiency and safety of Lamivudine used in decompensative hepatic cirrhosis (B) accompanied by hypersplenism].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Zhao NF, Su GG, Zhou Y.
PMID: 12601866
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(6):461-463. doi: 10.3785/j.issn.1008-9292.2002.06.015.

OBJECTIVE: To study the efficacy and safety in patients with decompensative hepatic cirrhosis treated with Lamivudine. METHODS: Eighteen decompensative hepatic cirrhosis (B) (active phage) patients accompanied with hypeersplenism were treated with Lamivudine 100mg po. per day. The total course...

Cite
Zhao NF, Su GG, Zhou Y. [Preliminary observation on the efficiency and safety of Lamivudine used in decompensative hepatic cirrhosis (B) accompanied by hypersplenism]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002;31(6):461-463doi: 10.3785/j.issn.1008-9292.2002.06.015.
Zhao, N. F., Su, G. G., & Zhou, Y. (2002). [Preliminary observation on the efficiency and safety of Lamivudine used in decompensative hepatic cirrhosis (B) accompanied by hypersplenism]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 31(6), 461-463. https://doi.org/10.3785/j.issn.1008-9292.2002.06.015
Zhao, Nian-Feng, et al. "[Preliminary observation on the efficiency and safety of Lamivudine used in decompensative hepatic cirrhosis (B) accompanied by hypersplenism]." Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences vol. 31,6 (2002): 461-463. doi: https://doi.org/10.3785/j.issn.1008-9292.2002.06.015
Zhao NF, Su GG, Zhou Y. [Preliminary observation on the efficiency and safety of Lamivudine used in decompensative hepatic cirrhosis (B) accompanied by hypersplenism]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(6):461-463. doi: 10.3785/j.issn.1008-9292.2002.06.015. Chinese. PMID: 12601866.
Copy Download .nbib Format: NLM
Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays.

Hepatology research : the official journal of the Japan Society of Hepatology

Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A, Habu D, Takeda T, Shiomi S, Seki S, Arakawa T, Nishiguchi S.
PMID: 12809940
Hepatol Res. 2003 Jun;26(2):125-133. doi: 10.1016/s1386-6346(03)00018-4.

Monitoring of hepatitis B virus (HBV) levels in serum plays an important role in the management of chronic hepatitis B in patients receiving lamivudine. We evaluated the usefulness of real-time quantitative polymerase chain reaction (TaqMan PCR) for the measurement...

Cite
Kohmoto M, Enomoto M, Yano Y, et al. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res. 2003;26(2):125-133doi: 10.1016/s1386-6346(03)00018-4.
Kohmoto, M., Enomoto, M., Yano, Y., Otani, S., Minamitani, S., Tamori, A., Habu, D., Takeda, T., Shiomi, S., Seki, S., Arakawa, T., & Nishiguchi, S. (2003). Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatology research : the official journal of the Japan Society of Hepatology, 26(2), 125-133. https://doi.org/10.1016/s1386-6346(03)00018-4
Kohmoto, Madoka, et al. "Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays." Hepatology research : the official journal of the Japan Society of Hepatology vol. 26,2 (2003): 125-133. doi: https://doi.org/10.1016/s1386-6346(03)00018-4
Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A, Habu D, Takeda T, Shiomi S, Seki S, Arakawa T, Nishiguchi S. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res. 2003 Jun;26(2):125-133. doi: 10.1016/s1386-6346(03)00018-4. PMID: 12809940.
Copy Download .nbib Format: NLM
Hepatitis B-lamivudine for all and forever?.

The American journal of gastroenterology

Souney PF.
PMID: 12907350
Am J Gastroenterol. 2003 Aug;98(8):1889-90. doi: 10.1111/j.1572-0241.2003.07624.x.

No abstract available.

Cite
Souney PF. Hepatitis B-lamivudine for all and forever?. Am J Gastroenterol. 2003;98(8):1889-90doi: 10.1111/j.1572-0241.2003.07624.x.
Souney, P. F. (2003). Hepatitis B-lamivudine for all and forever?. The American journal of gastroenterology, 98(8), 1889-90. https://doi.org/10.1111/j.1572-0241.2003.07624.x
Souney, Paul F. "Hepatitis B-lamivudine for all and forever?." The American journal of gastroenterology vol. 98,8 (2003): 1889-90. doi: https://doi.org/10.1111/j.1572-0241.2003.07624.x
Souney PF. Hepatitis B-lamivudine for all and forever?. Am J Gastroenterol. 2003 Aug;98(8):1889-90. doi: 10.1111/j.1572-0241.2003.07624.x. PMID: 12907350.
Copy Download .nbib Format: NLM
The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation.

Hepatology research : the official journal of the Japan Society of Hepatology

Ohkoshi S, Ogata N, Ichida T.
PMID: 12957201
Hepatol Res. 2003 Sep;27(1):13-17. doi: 10.1016/s1386-6346(03)00193-1.

The biochemical and virological outcomes of 19 patients with chronic hepatitis B who had been treated with 100 mg per day of lamivudine (LMV) for 1 year from 1995 to 1996 were evaluated. Fourteen patients were followed for 4.5-5...

Cite
Ohkoshi S, Ogata N, Ichida T. The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation. Hepatol Res. 2003;27(1):13-17doi: 10.1016/s1386-6346(03)00193-1.
Ohkoshi, S., Ogata, N., & Ichida, T. (2003). The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation. Hepatology research : the official journal of the Japan Society of Hepatology, 27(1), 13-17. https://doi.org/10.1016/s1386-6346(03)00193-1
Ohkoshi, Shogo, et al. "The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation." Hepatology research : the official journal of the Japan Society of Hepatology vol. 27,1 (2003): 13-17. doi: https://doi.org/10.1016/s1386-6346(03)00193-1
Ohkoshi S, Ogata N, Ichida T. The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation. Hepatol Res. 2003 Sep;27(1):13-17. doi: 10.1016/s1386-6346(03)00193-1. PMID: 12957201.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 800 entries